| ORIGINAL ARTICLE |
|
| Year : 2010 | Volume
: 1
| Issue : 2 | Page : 199-206 |
|
|
Formulation and evaluation of S-(-)-Amlodipine besylate and nebivolol hydrochloride tablets
SA Shaikh1, SS Shaikh2, SR Shahi3, MA Shookur4, LK Reddy1, AN Padalkar1, Mahesh Thube1
1 Jeevanjyoti Pharmaceutical, Aurangabad, Maharastra, India
2 Kamla Nehru College of Pharmacy, Aurangabad, Maharastra, India
3 Government College of Pharmacy, Aurangabad, Maharastra, India
4 Mulana Azad College of Arts and Science, Aurangabad, Maharastra, India
Correspondence Address:
S A Shaikh
Jeevanjyoti Pharmaceutical, Aurangabad, Maharastra
India
 Source of Support: None, Conflict of Interest: None  | Check |
PMID: 22247846 
|
|
|
The objective of the present study was to develop a tablet formulation of S-(-)amlodipine besylate chiral separation drug and nebivolol hydrochloride for better management of hypertension, while reducing or avoiding undesirable adverse effects, which are often associated with administration of a racemic mixture of amlodipine. The composition containing the optically pure S-(-)- isomer of amlodipine 2.5 mg has calcium channel blocking activity and, nebivolol hydrochloride 5 mg has beta-receptor blocking activity.
The study was also carried out to design a suitable dissolution medium for S-(-) - amlodipine besylate and nebivolol hydrochloride. Amlodipine besylate and nebivolol hydrochloride had maximum solubility in pH 1.2 and thus pH 1.2 was selected as the most suitable media for S-(-) - amlodipine besylate and nebivolol hydrochloride dissolution studies. The RSD below 2% indicated insignificant batch-to-batch variation. The accelerated stability study of the optimized formulation was performed as the ICH guidelines. The results indicated no change in optical rotation of S-(-) - amlodipine besylate. Hence, combination of two drugs can be formulated into the tablet by wet granulation technique having satisfactory release profile. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
